View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMETabolic EXplorer 과거 순이익 실적과거 기준 점검 0/6METabolic EXplorer 의 수입은 연평균 -239.2%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 3%의 비율로 증가했습니다. 매출은 연평균 36.4%의 비율로 감소해 왔습니다.핵심 정보-239.21%순이익 성장률-166.54%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률-36.39%자기자본이익률-51.87%순이익률-29.34%최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107% compared to a 15% decline forecast for the industry in the United Kingdom.Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).모든 업데이트 보기Recent updates공시 • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares IndexNew Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).New Risk • Oct 21New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.4m market cap, or US$12.1m).Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.New Risk • Sep 30New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€55m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€55m). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.Valuation Update With 7 Day Price Move • Jun 30Investor sentiment deteriorated over the past weekAfter last week's 47% share price decline to €2.17, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 39% over the past three years.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €4.59, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 155% over the past three years.Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107% compared to a 15% decline forecast for the industry in the United Kingdom.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to €4.92, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 23x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 252% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €4.56, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 22x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 228% over the past three years.Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).Is New 90 Day High Low • Mar 02New 90-day high: €4.76The company is up 113% from its price of €2.23 on 01 December 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.매출 및 비용 세부 내역METabolic EXplorer가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0GT7 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 23168-4930931 Mar 23198-5032931 Dec 22228-51331030 Sep 22246-33331030 Jun 22264-15331031 Mar 222183429931 Dec 211728324830 Sep 211057917730 Jun 2138759631 Mar 2120337631 Dec 202-94630 Sep 202-95630 Jun 202-85631 Mar 202-85631 Dec 192-85530 Sep 193-95530 Jun 193-95531 Mar 194-85531 Dec 186-65530 Sep 186-95630 Jun 187-115631 Mar 187-114631 Dec 177-114630 Sep 176-14630 Jun 17684631 Mar 17574731 Dec 16474730 Sep 16404730 Jun 164-74731 Mar 163-74731 Dec 153-74630 Sep 154-74630 Jun 154-64531 Mar 155-54531 Dec 146-44530 Sep 144-34430 Jun 143-24331 Mar 142-34231 Dec 131-44130 Sep 131-741양질의 수익: 0GT7 은(는) 현재 수익성이 없습니다.이익 마진 증가: 0GT7는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 0GT7의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 0GT7의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 0GT7은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-59.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 0GT7는 현재 수익성이 없으므로 자본 수익률이 음수(-51.87%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/03 22:40종가2024/05/06 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스METabolic EXplorer S.A.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Arsene GuekamCIC Market Solutions (ESN)Nicolas RoyotPortzamparc BNP ParibasChristophe Dombu YoutaPortzamparc BNP Paribas
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107% compared to a 15% decline forecast for the industry in the United Kingdom.
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
공시 • Oct 09METabolic EXplorer S.A.(ENXTPA:METEX) dropped from CAC AllShares IndexMETabolic EXplorer S.A. has been dropped from the CAC AllShares Index
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€8.78m market cap, or US$9.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Market cap is less than US$10m (€7.22m market cap, or US$7.76m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Feb 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€54m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€54m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€20.7m market cap, or US$22.3m).
New Risk • Oct 21New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €49m Forecast net loss in 2 years: €11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€54m). Currently unprofitable and not forecast to become profitable over next 2 years (€11m net loss in 2 years). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€11.4m market cap, or US$12.1m).
Reported Earnings • Oct 02First half 2023 earnings released: €0.33 loss per share (vs €0.51 loss in 1H 2022)First half 2023 results: €0.33 loss per share (improved from €0.51 loss in 1H 2022). Revenue: €69.9m (down 46% from 1H 2022). Net loss: €16.9m (loss narrowed 8.1% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom.
New Risk • Sep 30New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -€55m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€55m). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€25.4m market cap, or US$26.8m).
Reported Earnings • Oct 02First half 2022 earnings released: EPS: €0 (vs €2.70 in 1H 2021)First half 2022 results: EPS: €0 (down from €2.70 in 1H 2021). Revenue: €129.9m (up 250% from 1H 2021). Net loss: €18.4m (down 123% from profit in 1H 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment deteriorated over the past weekAfter last week's 47% share price decline to €2.17, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 39% over the past three years.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €4.59, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 155% over the past three years.
Reported Earnings • Apr 02Full year 2021 earnings releasedFull year 2021 results: Revenue: €171.6m (up €169.7m from FY 2020). Net income: €84.1m (up €93.1m from FY 2020). Profit margin: 49% (up from net loss in FY 2020). Over the next year, revenue is forecast to grow 107% compared to a 15% decline forecast for the industry in the United Kingdom.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to €4.92, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 23x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 252% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €4.56, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 22x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 228% over the past three years.
Reported Earnings • Apr 04Full year 2020 earnings releasedFull year 2020 results: Net loss: €8.94m (loss widened 8.5% from FY 2019).
Is New 90 Day High Low • Mar 02New 90-day high: €4.76The company is up 113% from its price of €2.23 on 01 December 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period.